

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of to respond to a collection of information unless it contains a unit 4 04/8 contains.

| Substitute for form 1449A/B/PTO | | | | Complete If Known | | |
|---------------------------------|-------------------|---------|--------------|------------------------|----------------|--|
| | , | | | Application Number | 10/090440 | |
| l IN | IFORMATION | 1 DI | SCLOSURE | Filing Date | March 4, 2002 | |
| STATEMENT BY APPLICANT | | | APPLICANT | First Named Inventor | Grant McFadden | |
| | | | | Art Unit | 1642 | |
| | (Use as many sh | eets a: | s necessary) | Examiner Name | M. Yu | |
| Sheet | 1 | of | 2 | Attorney Docket Number | MDSP-P01-002 | |

| | ==- | | U.S. PA | TENT DOCUMENTS | - |
|-----------|------|--|--|--|---|
| Examiner | Cite | Document Number | Publication Date MM-DD-YYYY 02-01-1994 | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where |
| Initials* | No. | Number-Kind Code ² (if known) | | | Relevant Passages or Relevant Figures Appear |
| ציות | AA | US-5,283,173 | | Fields et al. | |
| | AB | US-5,580,736 | 12-03-1996 | Brent et al. | |
| | AC | US-5,610,015 | 03-11-1997 | Wickens et al. | 1 |
| | AD | US-5,695,941 | 12-09-1997 | Brent et al. | |
| | AE | US-5,955,280 | 09-21-1999 | Vidal et al. | |
| J | AF | US-5,965,368 | 10-12-1999 | Vidal et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|--------------------------|--|-----------------------------------|--|---|--|--|--|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁸ (if known) | Publication Date MM-OD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | | |
| | | | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usplo.cox or MPEP 801.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Indication of the very of the reign of the Emperor must precede the serial number of the patent document. Indication of the very of the reign of the Emperor must precede the serial number of the patent document. Indication of the very of the reign of the Emperor must precede the serial number of the patent document. Indication of the very of the reign of the Emperor must precede the serial number of the patent document. Indication of the very of the reign of the Emperor must precede the serial number of the patent document. In this is the very of the very of the reign of the Emperor must precede the serial number of the patent document. In the very of t

| | | NON PATENT LITERATURE DOCUMENTS | |
|----------------------|-------------|---|----|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² |
| my | CA | Barry, M., et al., "The Myxoma Virus M-T4 Gene Encodes a Novel RDEL-Containing Protein that is Retained within the Endoplasmic Reticulum and is Important for the Productive Infection of Lymphocytes," Virology, 239:360-377 (1997). | |
| | СВ | Bartel, et al., "Elimination of False Positives That Arise in Using the Two-Hybrid System," BioTechniques, 14(6):920-924 (1993). | |
| | CC | Cheng, E.H.Y., et al., "Bax-independent inhibition of apoptosis by Bcl-xL," Nature, 379:554-556 (1996). | |
| | CD | Chittenden, T., et al., "A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions," EMBO J. 14:5589-5596 (1995). | |
| | CE | Graham, K.A., et al., "Myxoma Virus M11L ORF Encodes a Protein for Which Cell Surface Localization Is Critical in Manifestation of Viral Virulence," Virology, 191:112-124 (1992). | ٠. |
| | CF | Iwabuchi, K., et al., "Use of the two-hybrid system to identify the domain of p53 involved in oligomerization," Oncogene, 8:1693-1696 (1993). | • |
| | CG | Macen, J.L., et al., "Expression of the Myxoma Virus Tumor Necrosis Factor Receptor Homologue (T2) and M11L Genes is Required to Prevent Virus-Induced Apoptosis in Infected Rabbit T Lymphocytes," Virology, 218:232-237 (1996). | / |
| | СН | Madura, K., et al., "N-recognin/Ubc2 Interactions in the N-end Rule Pathway," J. Biol. Chem., 268:12046-54 (1993). | |
| | CI | McFadden, G. and Barry, M., "How Poxviruses Oppose Apoptosis," Semin. Virol., 8:429-442 (1998). | |
| V | C1 | Mossman, K., et al., "Disruption of M-T5, a Novel Myxoma Virus Gene Member of the Poxvirus Host Range Superfamily, Results in Dramatic Attenuation of Myxomatosis in Infected European Rabbits," J. Virol., 70(7):4394-4410 (1996). | |

| Examiner Signature | misol y | Date Considered | 3-19-05 |
|-----------------------|---------|--------------------|---------|
| | | | 0649009 |



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a val OMB continue.

| Substitute for form 1449A/B/PTQ | | | | Complete if Known | | |
|---------------------------------|------------------------|-----------|------------|------------------------|----------------|--|
| | | | | Application Number | 10/090440 | |
| 11 | IFORMATIC | ON DI | SCLOSURE | Filing Date | March 4, 2002 | |
| S | STATEMENT BY APPLICANT | | | First Named Inventor | Grant McFadden | |
| | | | | Art Unit | 1642 | |
| | (Use as many | sheets as | necessary) | Examiner Name | M. Yu | |
| Sheet | 2 | of | 2 | Attorney Docket Number | MDSP-P01-002 | |

| 317 | CK | Muchmore, S.W., et al., "X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death," Nature, 381:335-341 (1996). | |
|-----|----|--|--|
| Ī | CL | Oltvai, Z.N. and Korsmeyer, S.J., "Checkpoints of Dueling Dimers Foil Death Wishes," Cell, 79:189-192 (1994). | |
| | СМ | Opgenorth, A., et al., "Deletion Analysis of Two Tandemly Arranged Virulence Genes in Myxoma Virus, M11L and Myxoma Growth Factor," J. Virol., 66(8):4720-4731 (1992). | |
| | CN | Yin, X.M., et al., "BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax," Nature, 369:321-323 (1994). | |
| V | СО | Zervos, A.S., et al., "Mxi1, a Protein That Specifically Intereacts with Max to Bind Myc-Max Recognition Sites," Cell, 72:223-232 (1993). | |

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.